Modification of the ProC® Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 7, 2001, Pages 569-576

  Quincampoix, J C ^a   Legarff, M ^a   Rittling, C ^a   Andiva, S ^a   Toulon, Pierre ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

Activated protein C resistance; Factor V Leiden; Protein C; Protein S; Screening; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; BLOOD CLOTTING FACTOR 5; SNAKE VENOM;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD SAMPLING; CHILD; FEMALE; GENE MUTATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; THROMBOEMBOLISM; ACTIVATED PROTEIN C RESISTANCE; AGKISTRODON; ANIMAL; BLOOD; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; GENETICS; HETEROZYGOTE; HOMOZYGOTE; LIVER DISEASE; METHODOLOGY; MUTATION; PARTIAL THROMBOPLASTIN TIME; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; AGKISTRODON; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; CROTALID VENOMS; FACTOR V; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LIVER DISEASES; MUTATION; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

EID: 0034740060     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200110000-00010     Document Type: Article

References (36)

1. Mutation in blood coagulation factor V associated with resistance to activated protein C
2. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
3. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V
4. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study
5. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
6. World distribution of factor V Leiden
7. Myocardial infarction, Arg 506 to Gln mutation and activated protein C resistance
8. High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis
9. Inherited thrombophilia. Part 2
10. Diagnosis strategies in activated protein C resistance: Is genotyping still necessary?
11. The PCAT- a simple screening assay for assessing the functionality of the protein C anticoagulant pathway
12. Evaluation of a new screening assay ProC® Global for identification of defects in the protein C/protein S anticoagulant pathway
13. ProC® Global: The first functional screening assay for the complete protein C pathway
14. ProC® Global, a new assay to evaluate the functionality of the protein C anticoagulant pathway. Preliminary results in 223 consecutive patients with a history of venous thromboembolism
15. Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway
16. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter trial
17. A modified functional global test to measure protein C, protein S activities and the activated protein C-resistance phenotype
18. ProC Global: An automated screening test for factor V Leiden and prothrombin mutation 20210 G to A detection
19. A rapid screening method for the factor V Arg® Gln mutation
20. Fast functional protein C assay using Protac®*, a novel protein C activator
21. New direct assay for free protein S antigen using two distinct monoclonal antibodies specific for the free form
22. Criteria for the diagnosis of lupus anticoagulants: An update
23. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals
24. Resistance to activated protein C: Evaluation of three functional assays
25. Evaluation of APC-sensitivity in normal blood donors using different reagents and instruments
26. Specificity of an assay based on a Factor V-depleted plasma in patients carrying the Arg 506 Gln mutation
27. Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-R
28. A chromogenic assay for activated protein C resistance
29. Detecting APC-resistant factor V: A functional method without plasma dilution
30. The Factor V (Leiden) Test: Evaluation of an assay based on dilute Russell viper venom time in the detection of the factor V Leiden mutation
31. The use of two different APC resistance assay systems provides optimal sensitivity and specificity for diagnosing APC resistance
32. Modified test for activated protein C resistance
33. Modified APC resistance assay for patients on oral anticoagulants
34. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls
35. Screening for the FV:Q506 mutation - Evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis
36. A protein C pathway (PCP) screening test for the detection of APC resistance and protein C or S deficiencies